Trade Niagen Bioscience Inc - NAGE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0366 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 7.3617 |
| Open | 7.2517 |
| 1-Year Change | 114.8% |
| Day's Range | 7.2317 - 7.4017 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 7.3617 | 0.1600 | 2.22% | 7.2017 | 7.3917 | 7.0517 |
| Apr 23, 2025 | 7.1617 | 0.0300 | 0.42% | 7.1317 | 7.3817 | 7.1117 |
| Apr 22, 2025 | 6.8617 | 0.4400 | 6.85% | 6.4217 | 6.9117 | 6.4217 |
| Apr 21, 2025 | 6.5217 | -0.1100 | -1.66% | 6.6317 | 6.6617 | 6.3517 |
| Apr 17, 2025 | 6.7417 | 0.2400 | 3.69% | 6.5017 | 6.8017 | 6.4017 |
| Apr 16, 2025 | 6.5317 | 0.2300 | 3.65% | 6.3017 | 6.5517 | 6.2417 |
| Apr 15, 2025 | 6.3817 | 0.2800 | 4.59% | 6.1017 | 6.3817 | 6.1017 |
| Apr 14, 2025 | 6.1317 | 0.1400 | 2.34% | 5.9917 | 6.2517 | 5.9517 |
| Apr 11, 2025 | 5.9217 | 0.3300 | 5.90% | 5.5917 | 5.9217 | 5.5717 |
| Apr 10, 2025 | 5.6517 | -0.2900 | -4.88% | 5.9417 | 6.0517 | 5.5917 |
| Apr 9, 2025 | 6.0217 | 0.7200 | 13.58% | 5.3017 | 6.1717 | 5.3017 |
| Apr 8, 2025 | 5.3917 | -0.4500 | -7.70% | 5.8417 | 6.0317 | 5.3517 |
| Apr 7, 2025 | 5.6017 | -0.0600 | -1.06% | 5.6617 | 5.9617 | 5.3517 |
| Apr 4, 2025 | 6.0017 | -0.3300 | -5.21% | 6.3317 | 6.4817 | 5.8517 |
| Apr 3, 2025 | 6.6117 | -0.1500 | -2.22% | 6.7617 | 6.9617 | 6.5117 |
| Apr 2, 2025 | 7.0717 | 0.2600 | 3.82% | 6.8117 | 7.0817 | 6.7717 |
| Apr 1, 2025 | 6.8517 | 0.1400 | 2.09% | 6.7117 | 6.9317 | 6.6217 |
| Mar 31, 2025 | 6.8817 | 0.2800 | 4.24% | 6.6017 | 7.0617 | 6.6017 |
| Mar 28, 2025 | 6.7517 | -0.4700 | -6.51% | 7.2217 | 7.3017 | 6.7517 |
| Mar 18, 2025 | 7.8517 | 0.0200 | 0.26% | 7.8317 | 7.9017 | 7.7317 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Chromadex Corp Company profile
About Chromadex Corp
ChromaDex Corp. is a global bioscience company, which is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. NAD+ is a coenzyme and a regulator of cellular metabolism. It operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products that contain the ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Analytical reference standards and services segment supplies phytochemical reference standards and other research and development services. Its ingredients include Tru Niagen and Immulina. The Tru Niagen is a form nicotinamide riboside (NR). NR is a member of the vitamin B3 family. Immulina is a spirulina extract.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Chromadex Corp revenues increased 14% to $67.4M. Net loss increased 36% to $27.1M. Revenues reflect Consumer Products Segments increase of 20% to $56.7M, Analytical Reference Standards and Service segment increase of 12% to $3.3M. Higher net loss reflects Corporate and other segment loss increase of 19% to $36.4M, Ingredients Segments income decrease of 27% to $3.7M.
Equity composition
Common Stock $.001 Par, 08/11, 150M auth., 60,875,325 issd. Insiders & Strategic holders own 45.88%. 04/16, 1-for-3 recerse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
10900 Wilshire Blvd
Suite 600
LOS ANGELES
CALIFORNIA 90024
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com